Physician profile
James Kendall Eakin
NPI 1023688769
$647.21
in general payments reported to CMS, 2019-2025
13 companies · $378 in 2025
The $378 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.79 · 2022: $51.69 · 2023: $74.57 · 2024: $117 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $539 · Debt Forgiveness: $30.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $539.45 |
| Debt Forgiveness | $30.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $165.17 | 2024-2025 | Uzedy, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $107.09 | 2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $65.44 | 2025 | Invega Sustenna, Invega, Invega Trinza |
| E.R. Squibb & Sons, L.L.C. | $61.53 | 2025 | Cobenfy |
| Baxter Healthcare | $58.13 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $26.78 | 2025 | |
| Welch Allyn | $25.79 | 2021 | |
| Lundbeck LLC | $25.34 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $24.85 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.60 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $23.84 | 2022 | |
| Abbvie INC. | $19.69 | 2023 | |
| Neuronetics, INC. | $18.96 | 2025 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Eakin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.